CliffBio
small molecule

OMEPRAZOLE

OMEPRAZOLE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameOMEPRAZOLE
Active ingredientOMEPRAZOLE
Strength20MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2019
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.